key: cord-0873926-7ok6i3aa
authors: Carr, Edward J.; Kronbichler, Andreas; Graham-Brown, Matthew; Abra, Graham; Argyropoulos, Christos; Harper, Lorraine; Lerma, Edgar V.; Suri, Rita S.; Topf, Joel; Willicombe, Michelle; Hiremath, Swapnil
title: Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease
date: 2021-07-06
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.06.027
sha: 86e7008718e88620c656744b61071bc1665d3132
doc_id: 873926
cord_uid: 7ok6i3aa

INTRODUCTION: The effects of the coronavirus disease 19 (COVID-19) pandemic in particular affect those with chronic kidney disease (CKD), who commonly have defects in humoral and cellular immunity, and the efficacy of vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncertain. METHODS: To inform public health and clinical practice, we synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with CKD including those receiving dialysis or with a kidney transplant. RESULTS: We found 35 studies (28 published, 7 preprints), sample size from 23 to 1140 patients, and follow-up from one week to 1 month after vaccination. 17 of the 35 studies enrolled a control group. In the 22 studies of patients receiving dialysis, the development of antibodies was observed in 18 to 53% after one dose, and in 70 to 96% after two doses of mRNA vaccine. In the 14 studies of transplant recipients, 3% to 59% mounted detectable humoral or cellular responses after 2 doses of mRNA vaccine. After vaccination, there are a few reported cases of relapse or de novo glomerulonephritis, and acute transplant rejection suggesting ongoing surveillance is important. CONCLUSION: Studies are needed to better evaluate the effectiveness of SARS-CoV-2 vaccination in these populations. Rigorous surveillance for long-term adverse effects in patients with autoimmune disease and transplant recipients is required. For transplant recipients and those with suboptimal immune responses, alternate vaccination platforms and strategies should be considered. As additional data arise, the NephJC COVID-19 page will be updated (http://www.nephjc.com/news/covid-vaccine).

The effects of the coronavirus disease 19 (COVID- 19) pandemic have been far-reaching affecting people in all parts of the world. Few, if any, patient groups have been affected to the same extent as patients with chronic kidney disease (CKD). These patients have amongst the poorest of outcomes if they contract the virus and, in the case of patients on unit based haemodialysis (HD), have been unable to shelter in place to protect themselves [1] [2] .

Early and rapid vaccination is an absolute priority for this at-risk group, but while the results of vaccine trials have been impressive in the general population, the effectiveness of these vaccines have not been explicitly tested in patients with CKD who are often excluded from the trials (see Table 1 ) [3] . At this time clinical vaccine efficacy, immunogenicity and persistence of protection are known-unknowns in the patients with CKD (including transplant recipients) and patients with End Stage Kidney Disease (ESKD) [4] [5] . Understanding the response to vaccination in patients with CKD is a top priority for researchers and healthcare professionals who look after people with kidney disease. Given that seroconversion to the hepatitis B vaccine declines with advancing kidney disease and that seroconversion following the influenza vaccination is variable in patients on dialysis [6] it is not surprising that the international community has moved so quickly to gather and report data on the immune response to vaccination against COVID-19 in patients with kidney disease.

At the time of writing, the data available are heterogeneous, early-phase and reported in different ways making direct comparisons and quantitative synthesis difficult. Nevertheless, these early data are important and give a preliminary overview at the protection vaccination may confer for patients with kidney disease, accepting that none of the studies report the effects of vaccination on infection or mortality, rather the immune response, mostly as antibodies with a few studies on cellular activity.

In this narrative review we review and discuss the possible implications of the early vaccination data, whilst acknowledging this is a rapidly evolving area. Continued rigorous work J o u r n a l P r e -p r o o f and collaboration are essential to truly understand the protection vaccination will affordor not afford -patients with kidney disease, and to inform the current and future vaccination strategies.

This is a narrative review of the published and pre-printed literature on COVID-19 vaccines in CKD. We performed a literature search, with a hand search of pubmed and all nephrology and transplant journals since COVID-19 vaccination began. In addition, two preprint servers (biorxiv and medrxiv) were searched using the terms 'covid' 'vaccine' and 'kidney' or 'transplant' or 'dialysis'. Bibliographies of the included studies were reviewed for any eligible studies. Lastly, experts in the field and members of this workgroup reported additional studies the searches had missed. Data from the included studies was extracted by two authors (EC and SH) including details about patient population, antibody response, number of vaccine doses, type of antibody assay, safety data, and comorbidities. If possible, we removed individuals who were seropositive at the start of the study (i.e. had had a primary infection), who had incomplete data (eg baseline but no post vaccination results), and, again where possible, report percentage seropositivity for IgG alone. Our synthesis is shown in tables 2 and 3, and those numbers of patients and percentages are plotted against time in the figure. The main outcome being presented in this review is on antibody response, and we describe the limitations of interpreting these in the next section. A pooled estimate of the antibody response was performed using the random effects model as described by Dersimonian and Laird.

Before we review and describe the studies that have reported the response to vaccination in patients with kidney disease, it is worth highlighting that there are important limitations to consider, most of which are common to all the currently available studies.

Timing: Most studies report antibody response very early (the latest is 10 weeks after starting a vaccination course), and antibody response is at its most heterogeneous within these early weeks. In the phase I trial of the BNT162b2 mRNA vaccine, the development of anti-S antibodies was delayed by up to 1 week in year olds compared to 18-55 year olds [7] . Similarly, the kinetics described by Attias et al. in haemodialysis patients seems to be delayed by approximately a week compared to the age-matched Walsh cohort [7, 8] . An analogous delayed response has been reported in solid organ cancer patients after BNT162b2, given on days 0 and 21, with 38% seropositive at 3 weeks (n=56), rising to 95% at week 5 (n=19) [9] .

Peak antibody titres should therefore be expected after approximately 4 weeks in patients with significant comorbidities (renal or otherwise). Plotting the renal studies by their percentage seropositivity against time shows this relationship ( Figure 1 , full citations in tables 2 and 3).

Given the difficulties (see below) in comparing these studies directly, we view this as an illustrative framework to interpret the studies rather than a definitive statistical model. . The latter seem to best correlate with viral neutralisation and T-cell responses [11] . The assays in general are calibrated by the manufacturer against the wild type virus circulating in early 2020, but data about cutoffs against emerging variants of interest/concern are not available. Therefore, we have chosen to provide only the proportion of individuals who developed detectable anti-SARS-CoV-2 antibodies (herein called "seropositivity"). Whilst the World Health Organisation's initiative to establish a reference sample will go some way to allowing cross-platform comparisons (it has no impact on dynamic ranges), we must not conflate antibody levels reported in these early studies with precise clinical effectiveness [12] .

Prior exposure to SARS-CoV-2: Antibody responses to vaccination should also consider prior immunological exposure to SARS-CoV-2. For individuals with antigen experience from natural infection, a first vaccination triggers a secondary immune response. As a memory response, this provides antibodies in larger titres and more rapidly than the primary response in individuals without prior exposure. Exposure history is important in both the study (HD or transplant) and the comparator populations (often healthcare workers). Studies which do not measure, or report, baseline sero-status will be liable to comparing primary with secondary responders; this is a particular concern when comparing between studies, where the population prevalence of SARS-CoV-2 may be very different. In a resource-finite setting, the single most informative antibody measure is likely to be >4 weeks after the booster dose; clearly specific research studies may require earlier sampling.

The effectiveness of vaccination for patients with CKD has been studied at scale as part of the nationwide mass vaccination setting in Israel. This study included 8,212 patients with CKD, and reported a 74% protection against subsequent development of severe disease following both doses of BNT162b2 vaccine administration on the 3-week dosing schedule, however with a J o u r n a l P r e -p r o o f wide confidence interval (-40 to 100), suggesting these were based on a small number of events [13] . Although this was amongst the lowest rates of protection amongst the co-morbid populations studied, it might represent significant protection from disease for this patient group, if confirmed. Other large population-based studies have included a large sample of patients with CKD, but specific subgroup analyses are awaited [14] .

A paucity of data exists on the disease course of COVID-19 in patients on immunosuppression.

An analysis of the International Registry of COVID infection in glomerulonephritis indicated that mortality rates are comparable to those observed in dialysis and transplant patients [15] . There are specific considerations in these patient groups, which have been recently outlined by the

Transplant Association (ERA-EDTA) [16] . A concern is the antibody response of patients receiving induction phase immunosuppression or on maintenance therapy with rituximab, or other B cell depletion therapies (BCDT). Studies in rheumatoid arthritis indicate that there was no antibody response to influenza vaccination for four to eight weeks after rituximab administration [17] . The mRNA vaccine antibody response was studied in a cohort of 133 patients with chronic inflammatory diseases which reported that the use of BCDT was associated with a 36-fold reduction in anti-S IgG and neutralization titres in comparison to controls [18] . Reduced antibody response was more often observed in participants with an administration of BCDT within six months of vaccination, with a gradual recovery in response nine months after BCDT. Moreover, glucocorticoid use resulted in a significant decrease in vaccine response, as these patients exhibited a 10-fold reduction in anti-S IgG and neutralization titres [18] . Another chart review of 89 patients from a rheumatology practice revealed 21 patients (24%) did not develop antibodies after two doses of an mRNA vaccine, of whom 20 had been on rituximab, and the last patient on belimumab [19] . Similar to the earlier J o u r n a l P r e -p r o o f study, none of the 16 patients who received rituximab within 6 months of vaccination developed antibodies, only one of the 4 who had received rituximab between 6 and 12 months developed antibodies, whereas 9 of the 10 who had received rituximab 12 months or more prior to vaccination developed antibodies. From these initial data, the benefit of early vaccine administration after BCDT remains uncertain and research is needed to study the effects on cellular immunity and rate of infections, and the possible role of additional doses or alternate vaccine strategies in patients with no humoral response to vaccination. A change in strategy is being considered (i.e. the use of viral vector-based vaccines) and we hope more informed decisions can be made for this population in the coming weeks.

With respect to safety, activation of the immune system may potentially lead to a relapse or an increase in disease activity, or the declaration of an existing (but undiagnosed) condition.

At the time of writing, 7 case reports of minimal change disease are available, three as a relapse which responded to immunosuppression [20] [21] [22] [23] [24] [25] . The other 4 patients had a new diagnosis, three of them with acute kidney injury (AKI). Three of the four had responded to immunosuppression in the form of resolution of AKI, or reduction in proteinuria at the time of reporting. Similarly, there are 9 cases of IgA nephropathy, with 7 known to have IgA nephropathy in whom there was development of gross hematuria within hours of the vaccine doses, with spontaneous resolution [26] [27] [28] [29] [30] . Two patients however, were not known to have IgA nephropathy and developed crescentic IgA nephropathy and were still on treatment at the time of reporting. Two patients with c-ANCA vasculitis have also been reported as well as one patient with a relapse of membranous nephropathy [30] [31] [32] . The data is summarised in table 4. These are not unique to COVID vaccination; as an example, four cases of onset of nephrotic syndrome were identified in the year after meningococcal B vaccination in infants [33] . In large series, disease relapse after seasonal influenza vaccination is rare, and is probably consistent with underlying background rates [34] . All but one of the cases reported so far are after mRNA vaccines, which may reflect the selection bias on the vaccines administered so far. In addition, J o u r n a l P r e -p r o o f these are published cases only, with little information about the total vaccines administered to allow estimates of rates. An ongoing registry will provide more valuable data on how much of these reflect the underlying case rate that one should expect or an increase beyond expected incidence. These cases also emphasize the case for ongoing pharmacovigilance.

Defects in both humoral and cellular immunity are common in this population, which was well known even before the pandemic [35] . Responses to vaccination to hepatitis B, and influenza, are known to be suboptimal [36] . Responders to hepatitis B vaccination are generally younger, have a higher dialysis efficacy and serum albumin, and less likely have a diagnosis of diabetes mellitus [37] . Hence, most public health agencies have appropriately prioritized patients on dialysis based on high COVID-19 case fatality rate, and inability to self-isolate due to the need to come to the center for dialysis treatments in the majority. However, the efficacy of vaccination in this population is uncertain as they were not included in the original efficacy trials [38, 39] .

Several small studies investigating the role of COVID-19 vaccines in dialysis patients have been reported recently and are summarized in Table 2 [8, . The development of anti-SARS-CoV-2 antibodies is variable and depends on several factors, including the time from vaccine administration to antibody measurement, and the type of antibody assay. The first dose of an mRNA vaccine does not seem to induce anti-SARS-CoV-2 antibodies in the dialysis population, with the proportion having detectable antibodies ranging from 18 to 43% at 3-4 weeks after the 1 st dose, and one study reporting a higher response (73%) [8, 42, 48, 61] . Another study also reported higher antibody development (87%) however that was a select small group of 31 transplant waitlisted patients [57] . The pooled estimate of the antibody response rate was 45% (95% confidence interval [CI] 32% -58%). Most of the studies report data at 2-4 weeks after the first dose, and it is possible that development of antibodies is delayed in dialysis patients. However, in one study, patients without detectable anti-SARS-CoV-2 antibodies at 4 J o u r n a l P r e -p r o o f weeks did not develop them even after 8 week of observation, arguing against a delayed response in this population [54] . The development of antibodies to two doses of the mRNA vaccines is higher, ranging from 68% to 96%, with the caveat of additional time from the doses.

The pooled estimate after two doses is 89% (95% CI 85% -91%). A centre in France offered a third dose to 12 patients with non-response to 2 doses of BNT162b2. Among these patients, 5 (41.7%) had a seroconversion after the third dose [52] . Limited data exist on the efficacy of viral vector-based vaccines in dialysis patients, as only a single study reported on the outcome of 17 patients who received a single dose of AZD1222, which reported 71% antibody response compared to 80% with BNT162b2 (p = 0.3) [42] . Three studies reported the antibody response in PD patients, which seems numerically higher, at 63% after one dose at 96-97% after two doses [45, 51, 52] .

In the absence of an internationally accepted surrogate measure of efficacy for SARS-CoV-2 vaccination, it is difficult to know how to interpret the antibody levels in dialysis patients.

In those studies that compared antibody levels between dialysis and healthy controls (a population expected to have "optimal" antibody response), antibody levels in dialysis patients were significantly lower [40, 41, 43, 44, 46, 50, 61, 62] . Older age and immunosuppression or chemotherapy were associated with lower antibody levels and non-response in most studies, while other variables associated with no or reduced response were lower serum albumin, lower dialysis vintage, higher comorbidity, and higher intravenous iron sucrose doses in some studies.

With respect to safety, fewer side effects were reported following BNT162b2 administration in dialysis patients [62] .

A few studies report SARS-CoV-2 infections after vaccination. Among the six reported infections (from a cohort of 127 HD patients, 7 days or more after the second dose), one 79year-old male patient developed a severe disease course [41] . These patients all belonged to the group with the lowest antibody quartile. In the study from Goupil et al, 3 patients developed J o u r n a l P r e -p r o o f severe disease with COVID-19, with one death, and another in intensive care, though after the first dose of the vaccine only [54] .

Antibody response of kidney transplant recipients to hepatitis vaccines is comparable to the dialysis population [63] . Contrasting this, antibody response to mRNA vaccines in this population has been reported to be poor in several studies, ranging from 0 to 17% after the first dose, and 3 to 59% after two doses of the mRNA vaccine doses (Table 3) [43, 46, 57, [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . A pooled estimate of the antibody response after the first dose was 8% (95% CI 5% -15%) and after the second dose was 35 % (95% CI 29% -42%). [66] . Sattler et al. reported detectable spike-specific CD8+ T cells in only 2 of 39 kidney transplant recipients and a strongly impaired interleukin-2 production, while responder rates for CD4+ T helper cells were comparable to dialysis patients and controls [46] . Further analyses indicated that among kidney transplant recipients, the number of antigen specific B cells was lower, and these patients also exhibited signatures of inappropriate B cell memory induction [43] . Five studies so far have reported antibody levels in comparison to a control group and consistently reported a diminished response among transplant recipients [43, 46, 67, 68, 76] . Consistent risk factors for a lack of antibody response were older age, less time since transplant, and higher immunosuppression (maintenance with anti-metabolites, belatacept, triple immunosuppression) [68] [64, 65, 67] [66] .

Two studies included only patients on belatacept, with extremely low level of antibody response (0% and 2%) after the first vaccine dose, which did not increase much after the second dose (5% and 6%) [66, 73] . Similarly, another study reports that none of the 6 patients on belatacept developed antibodies after 2 doses [77] . One study reported a superior antibody response to mRNA-1273 (60%) over BNT162b2 (49%), and it will be important to see if this finding remains consistent across other studies [72] . . Notably, all the studies reported so far are with the mRNA J o u r n a l P r e -p r o o f vaccines, and no information is available at the time of writing on the immune response to other vaccine platforms for transplant recipients.

Apart from antibody response, several case series report development of COVID-19 after vaccination [68, [78] [79] [80] [81] [82] [83] [84] . In the study from Grupper et al, 2 patients (from 136) developed COVID-19 after full vaccination [68] . In the study from Rozen-Tvi et al, 4 (of 308 patients) developed COVID-19 after full vaccination, one with mild disease, three with severe disease of whom one died [71] . Another case series reports on 7 solid organ transplant recipients who developed COVID-19 despite one (n = 2) or 2 (n = 5) doses of the mRNA vaccines [80] . These recipients presenting with COVID-19 had undetectable or low titres of antibodies at the time of infection, and the disease course was comparable to non-vaccinated patients [80] . However, in a different case series, 13 patients developed COVID-19 (8 after two doses and the others after one dose of the 3 vaccine), of whom 3 were hospitalized, two in the intensive care unit and one died [79] . A case series from India (Meshram et al, Transplantation 2021) with the adenovirus vector vaccine (AZD122) of whom 2 developed after one dose and 2 after 2 doses. At the time of reporting, one had died, two were on mechanical ventilation and one recovered [84] . The largest case series so far is from France, of 55 patients who developed COVID 11 required hospitalization, 6 required intensive care and 3 died. In this study, they measured antibodies in 25 patients, and 24 had no response, and the one patient had a weak titre [78] . Overall, though we do not have a good sense of the actual rate of vaccine breakthrough, it does not seem uncommon, and is associated with an absent antibody response, or lower antibody titres.

At the time of writing there have been two reports of acute rejection following vaccination against COVID-19 [85, 86] . This has raised some alarm on social media, but these reports must be interpreted with caution. Previous reports do exist of low levels of de novo anti-HLA antibody development after vaccination for seasonal influenza and H1N1, though of uncertain clinical significance [87] . Though a causal link is difficult to prove on the basis of the two case reports so far, post-licensing surveillance is crucial to monitor and confirm or refute a possible signal.

Additionally, at this time, transplant patients and health care workers must not be put off having the COVID-19 vaccination based on these sparse data. Whilst the current data suggest there may be a diminished antibody response in this population, maintenance immunosuppression must be maintained throughout the vaccination period and not reduced as is being advocated in some patients with rheumatological conditions who are on disease modifying anti-rheumatic drugs. The risk benefit ratio when weighed against acute rejection for patients with a kidney transplant is very different to patients with rheumatological diseases [88] . Otherwise, the safety data of vaccination in transplant recipients is very reassuring in two large case series, with mostly local reactions and no anaphylaxis or neurological reactions [86] [Cucchiari] .

Vaccines are in general well tolerated in patients with kidney diseases. There is a clear recommendation to undergo vaccination. Evidence from the early vaccine studies indicates a low antibody response rate after one dose in dialysis patients, increasing to a possibly adequate antibody response rate after two doses, but antibody levels remain diminished compared to controls. Additionally, if antibody levels wane with time, booster doses will likely be needed, and possibly sooner than in the general population. The situation is different in kidney transplant recipients who fail (at least during the timeframe of these studies) to mount a detectable humoral response in a majority of patients, and alternative strategies may be needed. It seems essential that close contacts/household members of transplant recipients are prioritized, to provide some form of protection. Early studies highlight that the density of immunosuppression correlates with vaccine response and especially anti-metabolites impair antibody response. It is of importance to fully vaccinate (i.e. with two doses) dialysis patients on the deceased donor transplant waitlist, or those about to undergo live donor kidney transplants, as their response following transplantation will be more severely impaired, compared to the response while still on dialysis.

Reduction of vaccine hesitancy seems pivotal, and some centres might adopt a policy of denial of kidney transplantation if patients refuse vaccination due to non-medical reasons [89] .

Several arguments may reinforce such a strategy, but ethical considerations must be considered and withdrawal from the waitlist might be associated with legal issues. A national survey with 1515 responders from the US indicates about 20% vaccine hesitancy, driven by concerns of adverse effects [90] . Being Black, Native American, younger age women were associated with greater vaccine hesitancy. Vaccine hesitancy among staff needs to be reduced and experience from New York City indicated that thorough programs can reduce hesitancy to a low percentage [91] .

A systematic assessment of new onset disease or future relapse of glomerular diseases and acute rejection episodes in kidney transplant recipients is of importance as part of ongoing pharmacovigilance. Similar innate immune pathways are induced by mRNA vaccines and in systemic lupus erythematosus [5] . A monitoring of self-reported symptoms should be systematically collected during follow-up, such as is being done with the VACOLUP study [92] .

As discussed above patients with BCDT show an impaired humoral response to COVID-19 vaccines. Several recommendations have been made focusing on these patients. The

American College of Rheumatology suggests vaccination 4 weeks before the next cycle and administering the next rituximab dose 2 to 4 weeks after the second vaccine dose, if disease activity allows [93] . A delay in treatment should not increase relapse risk of the underlying kidney disease. The European League Against Rheumatism and the Immunonephrology Working Group of ERA-EDTA recommend that vaccination should be performed 6 months after the last rituximab dose [16, 93] . Even this approach may not be sufficient as the A potential approach is the switch to alternative immunosuppressive measures, i.e. azathioprine in the maintenance of ANCA-associated vasculitis, to increase the likelihood to achieve a humoral response. Studies to investigate the adoption of centre-based changes to the management of immune-mediated kidney diseases are on the way. Large studies with standardised antibody platforms: Studies are needed reporting data from several centres within one country or for instance the European Union. The REnal patients COVID-19 VACcination (RECOVAC) study is one such ongoing effort [94] . The studies reviewed here sketch a landscape, the detailed shading needs directly comparable data at scale. 

It is unclear so far if patients with no antibody response following vaccination are protected from severe disease courses or not. Antibody is only a facet of the vaccine response and other components of the response (e.g. primed T lymphocytes) may compensate to some degree.

Ideal strategies to boost the immune system: As more vaccine platforms become available, it might be of interest to switch vaccine platforms in non-responders (i.e. viral vector-based vaccines after failure to achieve a response following mRNA vaccines) or the role of additional booster doses.

Defining ideal assays to measure antibody response and perform studies on comparability:

In particular the need for defining threshold titres that tightly predicts clinical protection from mild, moderate and severe disease caused by the prevailing variant in the community. 

The early data that describe the antibody response following vaccination against COVID suggest the response may be lower in patients with CKD compared to the general population, but (particularly for patients with CKD and those on dialysis) there are reasons to be optimistic that for many, the response is robust. As more data are published, they will be continually updated on the NephJC COVID-19 vaccine page (http://www.nephjc.com/news/covid-vaccine).

Patients with a kidney transplant and those on immunosuppressive therapy the response appears diminished, but again there is evidence of the vaccines having a measurable effect.

Larger datasets which measure antibody neutralisation and outcome data following vaccination in all these patient groups are required to definitively understand vaccine effectiveness in patients with kidney disease and we strongly encourage international collaboration and data sharing between research groups to this end. 

Factors associated with COVID-19-related death using OpenSAFELY

The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action

The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19-a Rapid Review of International Registry Data

Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease

COVID-19 vaccines and kidney disease

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated Dial Transplant

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Minimal change disease relapse following SARS-CoV-2 mRNA vaccine

Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy

A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy

Is COVID-19 vaccination unmasking glomerulonephritis?

De novo vasculitis after mRNA-1273 (Moderna) vaccination

Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination

Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal

Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients

Immune Dysfunction in Uremia 2020

Factors That Influence the Immune Response to Vaccination

Hepatitis B virus vaccine immune response and mortality in dialysis patients: a metaanalysis

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients

Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms

Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients

Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis

Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients -a prospective cohort study

Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients

Immunogenicity of SARS-CoV-2 Vaccine in Dialysis

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

Humoral response of mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients

High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls

Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis

Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration

Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19

The humoral response to the BNT162b2 vaccine in hemodialysis patients 2021

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis 2021

Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study

Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared to Healthy Controls

A randomized controlled trial of comparative effectiveness between the 2 dose and 3 dose regimens of hepatitis a vaccine in kidney transplant recipients

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

of the mRNA-1273 SARS-CoV-2 vaccine

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients

Occurrence of severe COVID-19 in vaccinated transplant patients

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients

COVID-19 infection in Solid Organ Transplant Recipients after SARS-CoV-2 vaccination

Early Experience with SARs-CoV-2 mRNA Vaccine Breakthrough Among Kidney Transplant Recipients

Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients

Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination

Letter to Editor: COVID-19 in Kidney Transplant Recipients Vaccinated with Oxford-AstraZeneca COVID-19 vaccine (Covishield): A Single Center Experience from India

Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a kidney-transplant patient

Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation

The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy

SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey

COVID-19 Vaccination Acceptance and Hesitancy in Dialysis Staff: First Results From New York City

VACOLUP -CRMR des maladies auto-immunes de Strasbourg (RESO) n.d

Timing of COVID-19 Vaccine in the setting of anti-CD20 Therapy: A Primer for Nephrologists

The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant -a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium

J o u r n a l P r e -p r o o f